Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers.

Although children born to HIV-infected (HIV+) women receiving antiretroviral therapy during pregnancy show virtually no adverse clinical effects at birth, the antiretroviral nucleoside analog drugs are known to damage nuclear and mitochondrial DNA. In this study, biomarkers of mitochondrial toxicity and genotoxicity have been examined in a well-characterized sample set consisting of infants born to HIV-uninfected (HIV-) mothers (n = 30), and HIV- infants (n = 20) born to HIV-infected (HIV+) mothers who received either no antiretroviral therapy (n = 10) or zidovudine (3'-azido-3'-deoxythymidine [AZT]) during pregnancy (n = 10). DNA from cord blood leukocytes and peripheral blood leukocytes taken at 1 and 2 years of age was examined for loss of mitochondrial DNA (mtDNA) and telomere integrity. Telomere length, a measure of nuclear DNA damage, was the same in all infants at birth and at age 1 year. The quantity of mtDNA was assessed relative to nuclear DNA using a polymerase chain reaction-based chemiluminescence detection (PCR-CID) method that determined mitochondrial D Loop gene copies relative to nuclear 18S RNA gene copies by comparison with a standard curve. MtDNA quantity was expressed as a ratio of gene copy numbers. In infants of uninfected mothers (AZT-/HIV-) at the three time points, the ratios were 442 to 515, whereas in infants of untreated AZT-/HIV+ mothers the ratios were 261 to 297, and in infants of AZT-treated (AZT+/HIV+) mothers the ratios were 146 to 203. At all three time points, differences between the AZT-/HIV- group and the two HIV+ groups were statistically significant (p <.05), and differences between the AZT-/HIV+ and AZT+/HIV+ groups were also statistically significant (p <.05), demonstrating that AZT exposure causes a persistent depletion of mtDNA. The study shows that children of HIV+ mothers are at risk for mitochondrial damage that is further increased in infants of mothers receiving AZT during pregnancy.

[1]  S. Gortmaker,et al.  Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. , 1999, JAMA.

[2]  S. Staszewski,et al.  Evidence of Nucleoside Analogue Reverse Transcriptase Inhibitor‐Associated Genetic and Structural Defects of Mitochondria in Adipose Tissue of HIV‐Infected Patients , 2002, Journal of acquired immune deficiency syndromes.

[3]  L. Mofenson.  Technical report: perinatal human immunodeficiency virus testing and prevention of transmission. Committee on Pediatric Aids. , 2000, Pediatrics.

[4]  Kenneth A. Johnson,et al.  Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS Drugs* , 2001, The Journal of Biological Chemistry.

[5]  S. Lewin,et al.  Exposure to Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat , 2002, Journal of acquired immune deficiency syndromes.

[6]  P. van den Broek,et al.  The effect of ventilation tubes on language development in infants with otitis media with effusion: A randomized trial. , 2000, Pediatrics.

[7]  C. Geny,et al.  Zidovudine myopathy: A distinctive disorder associated with mitochondrial dysfunction , 1991, Annals of neurology.

[8]  D. Gomez,et al.  Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment. , 1998, Biochemical and biophysical research communications.

[9]  L. Kalish,et al.  Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[10]  P. Rustin,et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues , 1999, The Lancet.

[11]  W. Hauck,et al.  Prenatal zidovudine use and congenital anomalies in a medicaid population. , 2000 .

[12]  M. Gerschenson,et al.  Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? , 2002, Mitochondrion.

[13]  M. Dalakas,et al.  Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations , 2004, Acta Neuropathologica.

[14]  L. Anderson,et al.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. , 1997, Journal of the National Cancer Institute.

[15]  M. Dalakas,et al.  Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.

[16]  I. Larripa,et al.  Genotoxic activity of azidothymidine (AZT) in in vitro systems. , 1994, Mutation research.

[17]  P. Stratton,et al.  The Women and Infants Transmission Study (WITS) of Maternal-Infant HIV Transmission: Study Design, Methods, and Baseline Data , 1996 .

[18]  Peter J. Diggle,et al.  Testing for random dropouts in repeated measurement data. , 1989 .

[19]  Antiretroviral therapy during pregnancy and the risk of an adverse outcome. , 2002, The New England journal of medicine.

[20]  S. M. Barker,et al.  Concurrent Zidovudine‐Induced Myopathy and Hepatoxicity in Patients Treated for Human Immunodeficiency Virus (HIV) Infection , 1992, Pathology.

[21]  R. Tarone,et al.  Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. , 1999, AIDS.

[22]  S. Khoo,et al.  Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. , 1996, AIDS.

[23]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[24]  M. Poirier,et al.  Preferential incorporation of 3′‐azido‐2′,3′‐dideoxythymidine into telomeric DNA and Z‐DNA—containing regions of chinese hamster ovary cells , 1993, Molecular carcinogenesis.

[25]  M. Poirier,et al.  Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. , 2002 .

[26]  C. Klersy,et al.  Human immunodeficiency virus-related cancer in children: incidence and treatment outcome--report of the Italian Register. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Ramon C. Littell,et al.  Modelling covariance structure in the analysis of repeated measures data. , 2000 .

[28]  D. Gomez,et al.  Preferential incorporation of 3'-azido-2',3'-dideoxythymidine (azt) in telomeric sequences of cho cells. , 1995, International journal of oncology.

[29]  P. Tonin,et al.  AZT-induced mitochondrial myopathy , 1992, The Italian Journal of Neurological Sciences.

[30]  J. Schröder,et al.  Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine , 2004, Acta Neuropathologica.

[31]  Y. Yazdanpanah,et al.  Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy , 2000, AIDS.

[32]  J L Sullivan,et al.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.

[33]  P. Harrigan,et al.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.

[34]  M. Dalakas,et al.  Mitochondrial myopathy caused by long-term zidovudine therapy. , 1990, The New England journal of medicine.

[35]  L. Mofenson,et al.  Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts , 2000 .

[36]  R. Sinha,et al.  Highly sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring. , 2002, Carcinogenesis.

[37]  J. Beach.  Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. , 1998, Clinical therapeutics.

[38]  L. Anderson,et al.  Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. , 1999, Toxicology and applied pharmacology.

[39]  K. Brinkman.  Management of hyperlactatemia: no need for routine lactate measurements. , 2001, AIDS.